Lens / cognition-neuro
Sermorelin Cognition: What GHRH Trials in Older Adults Show
The strongest cognition signal comes from a controlled trial of a GHRH analog — with one caveat stated up front: most of this evidence uses related analogs, not sermorelin itself.
The short version
Sermorelin cognition is a real research question, with one honest limit. Sermorelin copies GHRH (the brain's "make growth hormone" signal), and that signalling system reaches the brain. In a controlled trial, a close cousin of sermorelin — a longer-lasting GHRH analog — improved thinking scores in older adults over 20 weeks [6]. In mice, other GHRH-class molecules lowered the proteins linked to Alzheimer's [7]. The catch: most of this work used related analogs, not sermorelin itself. So this describes GHRH-axis effects measured in studies — not a proven brain benefit of sermorelin in people.
The controlled cognition trial
The anchor finding is a randomized, double-blind, placebo-controlled trial of 152 older adults, 66 of them with mild cognitive impairment. Over 20 weeks, daily subcutaneous GHRH analog (tesamorelin, 1 mg before bedtime) had a favorable effect on cognition (P=0.03), with the effect strongest on executive function (P=0.005) [6]. The same trial raised IGF-1 by 117% — kept within the physiologic range — and reduced percent body fat by 7.4%, with adverse events characterized as mild [6]. It is registered as NCT00257712.
Two points keep the finding honest. The tested molecule was tesamorelin, a stabilized GHRH analog, not GHRH(1-29) itself. And a favorable effect over 20 weeks in a single trial is a signal worth documenting, not a settled claim about preventing cognitive decline.
Most of the cognition evidence on this page uses the related GHRH analog tesamorelin or GHRH agonist/antagonist analogs — not sermorelin itself. The signal belongs to the GHRH-analog class in controlled settings; there is no sermorelin-specific cognition trial in people.
The preclinical neuro tail
Below the human trial sits a set of animal and cell findings on GHRH-class molecules. In genetically modified 5XFAD Alzheimer's mice, the GHRH antagonist MIA-690 reduced Morris-water-maze escape latency and lowered brain amyloid-beta(1-42) and tau filament levels; in amyloid-beta-treated human HCN2 cortical cell cultures, a GHRH analog showed anti-oxidative, neuroprotective properties [7]. Administered into the lateral brain ventricle in mice, the GHRH antagonist MZ-4-71 improved consolidation of passive-avoidance learning, fully blocked beta-amyloid(25-35)-induced memory impairment, and produced antidepressant-like and mild anxiolytic effects without altering locomotion [8].
That both agonist and antagonist GHRH analogs appear neuroprotective in different models reflects how complex the axis is — a complexity catalogued in a 2025 Nature Reviews Endocrinology synthesis of GHRH biology across health and disease [12]. A 2026 rat study added a frontier signal: a sustained-release GHRH receptor agonist (MR-409, 10 mcg/rat/day) combined with mesenchymal stem cells resolved post-stroke vasogenic edema and reduced infarct size [13]. None of these are sermorelin clinical trials.
The GH/IGF-1 axis and the aging brain
The rationale connecting GHRH to cognition runs through IGF-1. A narrative review frames IGF-1 as a neurotrophic, neuroprotective factor and the GH/IGF-1 axis as a candidate therapeutic target in Alzheimer's disease — while noting GH responses to GHRH stimulation in Alzheimer's patients are equivocal, and that the cholinesterase inhibitor rivastigmine doubled the GH response to GHRH [9].
A counterweight comes from human imaging. In 13 adults with lifelong, untreated isolated GH deficiency from a GHRH-receptor gene mutation, versus 14 matched controls, MRI brain morphometry showed largely similar cortical thickness and regional volumes, and similar MRI-predicted versus chronological brain age [14]. Lifelong loss of GHRH-receptor signalling, in other words, did not appear to accelerate brain aging — a reminder that the axis's role in cognition is far from simple.
Lens questions
Two questions sit directly under the cognition lens.
Does sermorelin affect the brain?
GHRH and its analogs do act on the brain in research models: a randomized trial of a GHRH analog changed cognition alongside endocrine effects [6], and preclinical GHRH agonist and antagonist analogs reduced amyloid-beta, tau, and neuroinflammation in Alzheimer's-model mice [7]. These describe GHRH-axis neuroendocrine effects in studies, not a proven cognitive benefit of sermorelin in people.
Can GHRH improve cognition in older adults?
In a 152-person randomized, double-blind, placebo-controlled trial, 20 weeks of a daily bedtime GHRH analog (tesamorelin, 1 mg) had a favorable effect on cognition (P=0.03; executive function P=0.005) and raised IGF-1 by 117% within the physiologic range [6]. The signal is from the GHRH-analog class in a controlled setting, not a sermorelin-specific cognition trial.